An Open-label Observational Safety Study of Colobreathe® (colistimethate sodium dry powder for inhalation) Compared with Other Inhaled Anti-pseudomonal Antibiotics in Cystic Fibrosis Patients Using Cystic Fibrosis Registries

27/11/2016
10/03/2020
EU PAS number:
EUPAS16395
Study
Finalised
Documents
Study protocol
Study results
Study report
Other information